Abstract

Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive T-cell malignancy that arises in a proportion of individuals who are long-term carriers of human T-lymphotropic virus type 1. The median survival of aggressive subtypes is 8 to 10 months; with chemotherapy-based approaches, overall survival has remained largely unchanged in the ∼35 years since ATL was first described. Through the use of 4 representative case studies, we highlight advances in the biological understanding of ATL and the use of novel therapies such as mogamulizumab, as well as how they are best applied to different subtypes of ATL. We discuss the implementation of molecular methods that may guide diagnosis or treatment, although we accept that these are not universally available. In particular, we acknowledge discrepancies in treatment between different countries, reflecting current drug licensing and the difficulties in making treatment decisions in a rare disease, with limited high-quality clinical trial data.

REFERENCES

REFERENCES
1.
Gessain
A
,
Cassar
O
.
Epidemiological aspects and world distribution of HTLV-1 infection
.
Front Microbiol
.
2012
;
3
:
388
.
2.
Iwanaga
M
,
Watanabe
T
,
Yamaguchi
K
.
Adult T-cell leukemia: a review of epidemiological evidence
.
Front Microbiol
.
2012
;
3
:
322
.
3.
Iwanaga
M
.
Epidemiology of HTLV-1 infection and ATL in Japan: an update
.
Front Microbiol
.
2020
;
11
:
1124
.
4.
Shah
UA
,
Shah
N
,
Qiao
B
, et al
.
Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States
.
Cancer
.
2020
;
126
(
3
):
567
-
574
.
5.
Shah
UA
,
Chung
EY
,
Giricz
O
, et al
.
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies
.
Blood
.
2018
;
132
(
14
):
1507
-
1518
.
6.
Malpica
L
,
Pimentel
A
,
Reis
IM
, et al
.
Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States
.
Blood Adv
.
2018
;
2
(
6
):
607
-
620
.
7.
Rosadas
C
,
Puccioni‐Sohler
M
,
Oliveira
ACP
,
Casseb
J
,
Sousa
M
,
Taylor
GP
.
Adult T‐cell leukaemia/lymphoma in Brazil: a rare disease or rarely diagnosed?
Br J Haematol
.
2020
;
188
(
4
):
e46
-
e49
.
8.
Cook
LB
,
Rowan
AG
,
Melamed
A
,
Taylor
GP
,
Bangham
CR
.
HTLV-1–infected T cells contain a single integrated provirus in natural infection
.
Blood
.
2012
;
120
(
17
):
3488
-
3491
.
9.
Cook
LB
,
Melamed
A
,
Niederer
H
, et al
.
The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma
.
Blood
.
2014
;
123
(
25
):
3925
-
3931
.
10.
Iwanaga
M
,
Watanabe
T
,
Utsunomiya
A
, et al;
Joint Study on Predisposing Factors of ATL Development investigators
.
Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan
.
Blood
.
2010
;
116
(
8
):
1211
-
1219
.
11.
Malik
B
,
Taylor
GP
.
Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom
.
Br J Haematol
.
2019
;
184
(
6
):
1040
-
1043
.
12.
Demontis
MA
,
Hilburn
S
,
Taylor
GP
.
Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases
.
AIDS Res Hum Retroviruses
.
2013
;
29
(
2
):
359
-
364
.
13.
Rowan
AG
,
Dillon
R
,
Witkover
A
, et al
.
Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis
.
Blood
.
2020
;
135
(
23
):
2023
-
2032
.
14.
Ratner
L
.
Predicting the future: adult T-cell leukemia
.
Blood
.
2020
;
135
(
23
):
2013
-
2014
.
15.
Shimoyama
M
.
Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)
.
Br J Haematol
.
1991
;
79
(
3
):
428
-
437
.
16.
Sawada
Y
,
Hino
R
,
Hama
K
, et al
.
Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma
.
Blood
.
2011
;
117
(
15
):
3961
-
3967
.
17.
Bittencourt
AL
,
da Graças Vieira
M
,
Brites
CR
,
Farre
L
,
Barbosa
HS
.
Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients
.
Am J Clin Pathol
.
2007
;
128
(
5
):
875
-
882
.
18.
Tsukasaki
K
,
Imaizumi
Y
,
Tokura
Y
, et al
.
Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma
.
J Dermatol
.
2014
;
41
(
1
):
26
-
28
.
19.
Ishida
T
,
Joh
T
,
Uike
N
, et al
.
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study
.
J Clin Oncol
.
2012
;
30
(
8
):
837
-
842
.
20.
Bazarbachi
A
,
Plumelle
Y
,
Carlos Ramos
J
, et al
.
Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes
.
J Clin Oncol
.
2010
;
28
(
27
):
4177
-
4183
.
21.
Hodson
A
,
Laydon
DJ
,
Bain
BJ
,
Fields
PA
,
Taylor
GP
.
Pre-morbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia/lymphoma
.
Haematologica
.
2013
;
98
(
3
):
385
-
388
.
22.
Tsukasaki
K
,
Hermine
O
,
Bazarbachi
A
, et al
.
Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting
.
J Clin Oncol
.
2009
;
27
(
3
):
453
-
459
.
23.
Casulo
C
,
Schöder
H
,
Feeney
J
, et al
.
18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma
.
Leuk Lymphoma
.
2013
;
54
(
10
):
2163
-
2167
.
24.
Nakachi
S
,
Okada
M
,
Morishima
S
, et al
.
Clinical usefulness of FDG-PET/CT for the evaluation of various types of adult T-cell leukemia
.
Hematology
.
2017
;
22
(
9
):
536
-
543
.
25.
Cook
LB
,
Fuji
S
,
Hermine
O
, et al
.
Revised adult T-cell leukemia-lymphoma international consensus meeting report
.
J Clin Oncol
.
2019
;
37
(
8
):
677
-
687
.
26.
White
JD
,
Zaknoen
SL
,
Kasten-Sportès
C
, et al
.
Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma
.
Cancer
.
1995
;
75
(
7
):
1598
-
1607
.
27.
Tsukasaki
K
,
Tobinai
K
,
Shimoyama
M
, et al;
Lymphoma Study Group of the Japan Clinical Oncology Group
.
Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109)
.
Int J Hematol
.
2003
;
77
(
2
):
164
-
170
.
28.
Yamada
Y
,
Tomonaga
M
,
Fukuda
H
, et al
.
A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303
.
Br J Haematol
.
2001
;
113
(
2
):
375
-
382
.
29.
Tsukasaki
K
,
Utsunomiya
A
,
Fukuda
H
, et al;
Japan Clinical Oncology Group Study JCOG9801
.
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801
.
J Clin Oncol
.
2007
;
25
(
34
):
5458
-
5464
.
30.
Sakamoto
Y
,
Ishida
T
,
Masaki
A
, et al
.
CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment
.
Blood
.
2018
;
132
(
7
):
758
-
761
.
31.
Ishida
T
,
Jo
T
,
Takemoto
S
, et al
.
Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study
.
Br J Haematol
.
2015
;
169
(
5
):
672
-
682
.
32.
Ishida
T
,
Jo
T
,
Takemoto
S
, et al
.
Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation
.
Br J Haematol
.
2019
;
184
(
3
):
479
-
483
.
33.
Fuji
S
,
Shindo
T
.
Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma
.
Stem Cell Investig
.
2016
;
3
:
70
.
34.
Nakashima
M
,
Yamochi
T
,
Watanabe
M
, et al
.
CD30 characterizes polylobated lymphocytes and disease progression in HTLV-1–infected individuals
.
Clin Cancer Res
.
2018
;
24
(
21
):
5445
-
5457
.
35.
Horwitz
S
,
O’Connor
OA
,
Pro
B
, et al;
ECHELON-2 Study Group
.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
.
Lancet
.
2019
;
393
(
10168
):
229
-
240
.
36.
Fuji
S
,
Fujiwara
H
,
Nakano
N
, et al;
ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation
.
Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma
.
Bone Marrow Transplant
.
2016
;
51
(
2
):
205
-
211
.
37.
Bazarbachi
A
,
Cwynarski
K
,
Boumendil
A
, et al
.
Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP
.
Bone Marrow Transplant
.
2014
;
49
(
10
):
1266
-
1268
.
38.
Utsunomiya
A
.
Progress in allogeneic hematopoietic cell transplantation in adult T-cell leukemia-lymphoma
.
Front Microbiol
.
2019
;
10
:
2235
.
39.
Rowan
AG
,
Witkover
A
,
Melamed
A
, et al
.
T cell receptor Vβ staining identifies the malignant clone in adult T cell leukemia and reveals killing of leukemia cells by autologous CD8+ T cells
.
PLOS Pathog
.
2016
;
12
(
11
):
e1006030
.
40.
Marçais
A
,
Cook
L
,
Witkover
A
, et al
.
Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma
.
Retrovirology
.
2020
;
17
(
1
):
5
.
41.
Phillips
AA
,
Fields
PA
,
Hermine
O
, et al
.
Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
.
Haematologica
.
2019
;
104
(
5
):
993
-
1003
.
42.
Sharma
K
,
Janik
JE
,
O’Mahony
D
, et al
.
Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma
.
Clin Cancer Res
.
2017
;
23
(
1
):
35
-
42
.
43.
Ishida
T
,
Fujiwara
H
,
Nosaka
K
, et al
.
Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002
.
J Clin Oncol
.
2016
;
34
(
34
):
4086
-
4093
.
44.
Ratner
L
,
Rauch
D
,
Abel
H
, et al
.
Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma
.
Blood Cancer J
.
2016
;
6
(
3
):
e408
.
45.
Ishitsuka
K
,
Utsunomiya
A
,
Katsuya
H
, et al
.
A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma
.
Cancer Sci
.
2015
;
106
(
9
):
1219
-
1223
.
46.
Ceesay
M
,
Matutes
E
,
Taylor
GP
, et al
.
Phase II study on combination therapy with CHOP-Zenapax for HTLV-1 associated adult T cell leukemia/lymphoma (ATLL)
.
Leukemia Research
.
2012
;
36
(
7
):
857
-
861
.
47.
Hodson
A
,
Crichton
S
,
Montoto
S
, et al
.
Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma
.
J Clin Oncol
.
2011
;
29
(
35
):
4696
-
4701
.
48.
Ratner
L
,
Harrington
W
,
Feng
X
, et al;
AIDS Malignancy Consortium
.
Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma
.
PLoS One
.
2009
;
4
(
2
):
e4420
.
49.
Kchour
G
,
Tarhini
M
,
Kooshyar
M-M
, et al
.
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)
.
Blood
.
2009
;
113
(
26
):
6528
-
6532
.
50.
Hermine
O
,
Dombret
H
,
Poupon
J
, et al
.
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma
.
Hematol J
.
2004
;
5
(
2
):
130
-
134
.
51.
Sorror
ML
,
Maris
MB
,
Storb
R
, et al
.
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
.
Blood
.
2005
;
106
(
8
):
2912
-
2919
.
52.
Yoshimitsu
M
,
Tanosaki
R
,
Kato
K
, et al;
ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation
.
Risk assessment in adult T cell leukemia/lymphoma treated with allogeneic hematopoietic stem cell transplantation
.
Biol Blood Marrow Transplant
.
2018
;
24
(
4
):
832
-
839
.
53.
Einsiedel
L
,
Fernandes
L
,
Spelman
T
,
Steinfort
D
,
Gotuzzo
E
.
Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population
.
Clin Infect Dis
.
2012
;
54
(
1
):
43
-
50
.
54.
Honarbakhsh
S
,
Taylor
GP
.
High prevalence of bronchiectasis is linked to HTLV-1-associated inflammatory disease
.
BMC Infect Dis
.
2015
;
15
:
258
.
55.
Oka
S
,
Ono
K
,
Nohgawa
M
.
Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
.
Leuk Res Rep
.
2019
;
11
:
21
-
23
.
56.
Matsushita
K
,
Matsumoto
T
,
Ohtsubo
H
, et al
.
Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma
.
Leuk Lymphoma
.
1999
;
36
(
1-2
):
67
-
75
.
57.
Takasaki
Y
,
Iwanaga
M
,
Imaizumi
Y
, et al
.
Long-term study of indolent adult T-cell leukemia-lymphoma
.
Blood
.
2010
;
115
(
22
):
4337
-
4343
.
58.
Seegulam
ME
,
Ratner
L
.
Integrase inhibitors effective against human T-cell leukemia virus type 1
.
Antimicrob Agents Chemother
.
2011
;
55
(
5
):
2011
-
2017
.
59.
Macchi
B
,
Balestrieri
E
,
Ascolani
A
, et al
.
Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors
.
Viruses
.
2011
;
3
(
5
):
469
-
483
.
60.
Cook
LB
,
Elemans
M
,
Rowan
AG
,
Asquith
B
.
HTLV-1: persistence and pathogenesis
.
Virology
.
2013
;
435
(
1
):
131
-
140
.
61.
Kannagi
M
,
Hasegawa
A
,
Takamori
A
,
Kinpara
S
,
Utsunomiya
A
.
The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases
.
Front Microbiol
.
2012
;
3
:
323
.
62.
Matsuoka
M
,
Jeang
KT
.
Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation
.
Nat Rev Cancer
.
2007
;
7
(
4
):
270
-
280
.
63.
Kinpara
S
,
Kijiyama
M
,
Takamori
A
, et al
.
Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells
.
Retrovirology
.
2013
;
10
:
52
.
64.
Macchi
B
,
Balestrieri
E
,
Frezza
C
, et al
.
Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α
.
Blood Adv
.
2017
;
1
(
12
):
748
-
752
.
65.
Journo
C
,
Mahieux
R
.
HTLV-1 and innate immunity
.
Viruses
.
2011
;
3
(
8
):
1374
-
1394
.
66.
Gill
PS
,
Harrington
W
Jr.
,
Kaplan
MH
, et al
.
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine
.
N Engl J Med
.
1995
;
332
(
26
):
1744
-
1748
.
67.
Hermine
O
,
Allard
I
,
Lévy
V
,
Arnulf
B
,
Gessain
A
,
Bazarbachi
A
;
French ATL Therapy Group
.
A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma
.
Hematol J
.
2002
;
3
(
6
):
276
-
282
.
68.
White
JD
,
Wharfe
G
,
Stewart
DM
, et al
.
The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma
.
Leuk Lymphoma
.
2001
;
40
(
3-4
):
287
-
294
.
69.
Cook
LB
,
Rowan
AG
,
Demontis
MA
, et al
.
Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma
.
Int J Hematol
.
2018
;
107
(
3
):
378
-
382
.
70.
Cook
LBM
,
Demontis
MA
,
Sagawe
S
, et al
.
Molecular remissions are observed in chronic adult T cell leukemia/lymphoma in patients treated with mogamulizumab
.
Haematologica
.
2019
;
104
(
12
):
e566
-
e569
.
71.
Fuji
S
,
Kato
K
,
Nakano
N
, et al
.
Pre- and posttransplant use of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma: a statement from key opinion leaders in Japan
.
Adv Cell Gene Ther
.
2018
;
1
(
1
):
e5
.
72.
Fuji
S
,
Inoue
Y
,
Utsunomiya
A
, et al
.
Pretransplantation Anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality
.
J Clin Oncol
.
2016
;
34
(
28
):
3426
-
3433
.
73.
Sugio
T
,
Kato
K
,
Aoki
T
, et al
.
Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease
.
Biol Blood Marrow Transplant
.
2016
;
22
(
9
):
1608
-
1614
.
74.
Ishida
T
,
Utsunomiya
A
,
Jo
T
, et al
.
Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies
.
Cancer Sci
.
2017
;
108
(
10
):
2022
-
2029
.
75.
Takemori
N
,
Hirai
K
,
Onodera
R
, et al
.
Satisfactory remission achieved by PUVA therapy in a case of crisis-type adult T-cell leukaemia/lymphoma with generalized cutaneous leukaemic cell infiltration
.
Br J Dermatol
.
1995
;
133
(
6
):
955
-
960
.
76.
Kudo
H
,
Fukushima
S
,
Masuguchi
S
,
Sakai
K
,
Jinnin
M
,
Ihn
H
.
Cutaneous type adult T-cell leukaemia/lymphoma successfully treated with narrowband ultraviolet B phototherapy
.
Clin Exp Dermatol
.
2012
;
37
(
2
):
183
-
184
.
77.
Kataoka
K
,
Nagata
Y
,
Kitanaka
A
, et al
.
Integrated molecular analysis of adult T cell leukemia/lymphoma
.
Nat Genet
.
2015
;
47
(
11
):
1304
-
1315
.
78.
Kataoka
K
,
Iwanaga
M
,
Yasunaga
JI
, et al
.
Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
.
Blood
.
2018
;
131
(
2
):
215
-
225
.
79.
Kataoka
K
,
Shiraishi
Y
,
Takeda
Y
, et al
.
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
.
Nature
.
2016
;
534
(
7607
):
402
-
406
.
80.
Yoshida
N
,
Shigemori
K
,
Donaldson
N
, et al
.
Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions
.
Blood
.
2020
;
135
(
17
):
1467
-
1471
.
81.
O’Connor
OA
,
Horwitz
S
,
Hamlin
P
, et al
.
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
.
J Clin Oncol
.
2009
;
27
(
26
):
4357
-
4364
.
82.
Lunning
MA
,
Gonsky
J
,
Ruan
J
, et al
.
Pralatrexate in relapsed/refractory HTLV-1 associated adult T-cell lymphoma/leukemia: a New York city multi-institutional experience
.
Blood
.
2012
;
120
(
21
):
2735
-
2735
.
83.
Barr
PM
,
Li
H
,
Spier
C
, et al
.
Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108
.
J Clin Oncol
.
2015
;
33
(
21
):
2399
-
2404
.
84.
Mukhi
N
,
Verma
V
,
Ahmed
A
,
Lim
H
,
Gonsky
J
,
Sidhu
G
.
Romidepsin in relapsed/refractory HTLV-1 associated adult T-cell lymphoma/leukemia: a case series
.
Blood
.
2015
;
126
(
23
):
5113
-
5113
.
85.
Phillips
AA
,
Giddings
J
,
Lee
SM
,
Horwitz
SM
.
Lenalidomide in patients with relapsed or refractory HTLV-1 related adult T cell leukemia/lymphoma (ATLL)
.
Int J Blood Res Disord
.
2015
;
2
(
1
):
86.
Ratner
L
,
Waldmann
TA
,
Janakiram
M
,
Brammer
JE
.
Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy
.
N Engl J Med
.
2018
;
378
(
20
):
1947
-
1948
.
87.
El-Sabban
ME
,
Nasr
R
,
Dbaibo
G
, et al
.
Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation
.
Blood
.
2000
;
96
(
8
):
2849
-
2855
.
88.
Simone
CB
II
,
Morris
JC
,
Stewart
DM
, et al
.
Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma
.
Blood
.
2012
;
120
(
9
):
1816
-
1819
.
89.
Maruyama
D
,
Tobinai
K
,
Makita
S
, et al
.
First-in-human study of the EZH1/2 dual inhibitor DS-3201b in patients with relapsed or refractory non-Hodgkin lymphomas – preliminary results [abstract]
.
Blood
.
2017
;
130
(
suppl 1
).
Abstract 4070
.
90.
Morishima
S
,
Ishitsuka
K
,
Izutsu
K
, et al
.
First-in-human study of the EZH1/2 dual inhibitor valemetostat in relapsed or refractory non-Hodgkin lymphoma (NHL) – updated results focusing on adult T-cell leukemia-lymphoma (ATL) [abstract]
.
Blood
.
2019
;
134
(
suppl 1
).
Abstract 4025
.
91.
Yamagishi
M
,
Hori
M
,
Fujikawa
D
, et al
.
Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas
.
Cell Rep
.
2019
;
29
(
8
):
2321
-
2337.e7
.
92.
Suehiro
Y
,
Hasegawa
A
,
Iino
T
, et al
.
Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study
.
Br J Haematol
.
2015
;
169
(
3
):
356
-
367
.
You do not currently have access to this content.

Sign in via your Institution

Sign In